Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma

L. Brambilla, R. Labianca, S. Fossati, V. Boneschi, S. Ferrucci, M. Clerici, G. Dallavalle

Research output: Contribution to journalArticlepeer-review


A phase II evaluation of Vinorelbine is of interest in mediterranean Kaposi's sarcoma (MKS) because of the well-known activity of the natural Vinca alkaloids in this disease. Fifteen patients, both chemonaive and pretreated, were treated with Vinorelbina at the close level of 17.5 mg/sqm every 2 weeks, 5 times, then 30 mg/sqm every 3 weeks until maximal response (complete regression, or partial regression), followed by 3 consolidation courses. A partial regression was obtained in 9/15 (60%) patients, with higher activity in previously untreated patients as compared to pretreated patients. The duration of remission was 6 months in the first group and 2 months in the second one. The median survival (all patients) was 13+ months. Vinorelbine is an active drug in MKS and needs more extensive, evaluation in large, cooperative clinical trials.

Original languageEnglish
Pages (from-to)467-469
Number of pages3
JournalEuropean Journal of Dermatology
Issue number6
Publication statusPublished - 1995


  • Chemotherapy
  • Mediterranean Kaposi's sarcoma
  • Vinorelbine

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this